Department of Surgery, General Surgery Service, Brooke Army Medical Center, Ft. Sam Houston, TX 78234, USA.
Vaccine. 2010 Nov 3;28(47):7476-82. doi: 10.1016/j.vaccine.2010.09.029. Epub 2010 Sep 19.
Regulatory T cells (T(Reg)), CD4(+)CD25(+)FOXP3(+), are implicated in suppressing tumor immune responses. We analyzed peripheral blood lymphocytes (PBL) from breast cancer patients receiving a modified HLA class II HER2/neu peptide (AE37) vaccine for T(Reg) cells and correlated their levels with vaccine-specific immune responses. The mean CD4(+)CD25(+)FOXP3(+) T(Reg) cells decreased in patients with vaccination with no significant difference in serum TGF-β levels. IFN-γ ELISPOT and DTH increased after vaccination with a good correlation between T(Reg) cell reduction and size of DTH to AE37. The T(Reg) cell reduction and associated immune response suggest that AE37 may be clinically useful.
调节性 T 细胞（T(Reg)），CD4(+)CD25(+)FOXP3(+)，被认为在抑制肿瘤免疫反应中发挥作用。我们分析了接受改良 HLA Ⅱ类 HER2/neu 肽（AE37）疫苗的乳腺癌患者的外周血淋巴细胞（PBL）中的 T(Reg)细胞，并将其水平与疫苗特异性免疫反应相关联。接受疫苗接种的患者中 CD4(+)CD25(+)FOXP3(+)T(Reg)细胞的平均值下降，而血清 TGF-β 水平没有显著差异。IFN-γ ELISPOT 和 DTH 在疫苗接种后增加，T(Reg)细胞减少与 AE37 的 DTH 大小之间存在良好的相关性。T(Reg)细胞减少和相关的免疫反应表明，AE37 可能具有临床应用价值。
